COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

May 15, 2023

Kinaset Therapeutics to Present at the American Thoracic Society (ATS) 2023 Respiratory Innovation Summit

Jul 7, 2022

Kinaset Therapeutics Appoints Christopher O’Brien, MD, PhD, FCCP, as Chief Medical Officer

Sep 15, 2021

Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients

Nov 30, 2020

Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory

For More Press Releases

---